The stock of Terns Pharmaceuticals Inc (TERN) has gone up by 0.64% for the week, with a 2.19% rise in the past month and a 12.82% rise in the past quarter. The volatility ratio for the week is 6.02%, and the volatility levels for the past 30 days are 7.84% for TERN. The simple moving average for the past 20 days is 7.84% for TERN’s stock, with a 22.71% simple moving average for the past 200 days.
Is It Worth Investing in Terns Pharmaceuticals Inc (NASDAQ: TERN) Right Now?
Company’s 36-month beta value is -0.38.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TERN is 47.96M, and currently, short sellers hold a 3.76% ratio of that floaft. The average trading volume of TERN on August 29, 2024 was 1.27M shares.
TERN) stock’s latest price update
The stock price of Terns Pharmaceuticals Inc (NASDAQ: TERN) has surged by 2.86 when compared to previous closing price of 7.70, but the company has seen a 0.64% gain in its stock price over the last five trading sessions. zacks.com reported 2024-08-28 that The consensus price target hints at a 78.7% upside potential for Terns Pharmaceuticals (TERN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Analysts’ Opinion of TERN
Many brokerage firms have already submitted their reports for TERN stocks, with Mizuho repeating the rating for TERN by listing it as a “Buy.” The predicted price for TERN in the upcoming period, according to Mizuho is $16 based on the research report published on June 22, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see TERN reach a price target of $18. The rating they have provided for TERN stocks is “Buy” according to the report published on June 07th, 2023.
ROTH MKM gave a rating of “Buy” to TERN, setting the target price at $23 in the report published on May 31st of the previous year.
TERN Trading at 2.80% from the 50-Day Moving Average
After a stumble in the market that brought TERN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.04% of loss for the given period.
Volatility was left at 7.84%, however, over the last 30 days, the volatility rate increased by 6.02%, as shares surge +2.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.28% upper at present.
During the last 5 trading sessions, TERN rose by +1.40%, which changed the moving average for the period of 200-days by +126.70% in comparison to the 20-day moving average, which settled at $7.35. In addition, Terns Pharmaceuticals Inc saw 22.03% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TERN starting from Quigley Jill M., who sale 8,857 shares at the price of $7.50 back on Aug 02 ’24. After this action, Quigley Jill M. now owns 15,000 shares of Terns Pharmaceuticals Inc, valued at $66,432 using the latest closing price.
Quigley Jill M., the Director of Terns Pharmaceuticals Inc, sale 6,143 shares at $7.68 during a trade that took place back on Aug 01 ’24, which means that Quigley Jill M. is holding 23,857 shares at $47,148 based on the most recent closing price.
Stock Fundamentals for TERN
Current profitability levels for the company are sitting at:
- -81.86 for the present operating margin
- 0.31 for the gross margin
The net margin for Terns Pharmaceuticals Inc stands at -72.54. The total capital return value is set at -0.49. Equity return is now at value -38.92, with -36.84 for asset returns.
Based on Terns Pharmaceuticals Inc (TERN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -317.24. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -42.13.
Currently, EBITDA for the company is -101.68 million with net debt to EBITDA at 0.85. When we switch over and look at the enterprise to sales, we see a ratio of 348.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.02.
Conclusion
In a nutshell, Terns Pharmaceuticals Inc (TERN) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
